Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 263 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Heart Failure With Preserved Ejection Fraction Clear all

Conditions: Chronic Heart Failure With Preserved Ejection Fraction
Interventions: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 29
States / cities: Beverly Hills, California • Carmichael, California • West Hills, California + 26 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: PeriCut Catheter System performs minimally invasive pericardiotomy; Device
Lead sponsor: Heart Failure Solutions, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: WHOOP strap 3.0; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity, Heart Failure
Interventions: NNC0487-0111, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 5,610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 206
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more

Conditions: Chronic Heart Failure
Interventions: MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin; Biological · Drug
Lead sponsor: Melana Yuzefpolskaya, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Static Handgrip, Dexmedetomidine, Glycopyrrolate, Isoproterenol; Other · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: Weight loss SOC Treatment with second generation anti-diabetic medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 6,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 120
States / cities: Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more

Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions: JK07; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Heart Failure
Interventions: AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor; Device
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 50
States / cities: Fairhope, Alabama • Beverly Hills, California • Los Angeles, California + 41 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Nutritional and Dietary Manipulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: VS-041, Placebo; Drug · Other
Lead sponsor: Vasa Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Little Rock, Arkansas • Huntington Beach, California • Santa Maria, California + 18 more

Conditions: Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
Interventions: Individualized myPACE pacemaker programming; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 51
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5,988 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 135
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions: Pulmonary Artery Denervation (PADN), Sham procedure control; Device
Lead sponsor: Pulnovo Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 14
States / cities: Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 9 more

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions: Dobutamine, Amlodipine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: HU6, Placebo; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Beverly Hills, California • Torrance, California • Hialeah, Florida + 11 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: HF Kit and Follow-ups; Behavioral
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Brick, New Jersey

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Type 2 Diabetes, Heart Failure
Interventions: Oral semaglutide, Sitagliptin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)

Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients

Wearable Remote Monitoring of Heart Rate and Respiratory Rate for Heart Failure

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

Chronotropic Incompetence in Patients With HFpEF

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

Radiofrequency (RF) Ablation for Atrial Fibrillation (AF) in Patients With Heart Failure With Preserved Ejection Fraction

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

REALIsM-HF Pilot Study

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

Ketogenic Diet in Patients With Heart Failure

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

PrEcision Pacing in HFpEF: the PEP-HFpEF Trial

Study of JK07 in Patients With Chronic Heart Failure

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Transitions of Care Clinic (TOCC)

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)